Targeting menin for precision therapy in high-risk acute myeloid leukemia

被引：0
|
作者：
Jamil, Abdur [1 ]
Qureshi, Zaheer [2 ]
El-amir, Zain Mary [3 ]
Kupakuwana-Suk, Gillian [4 ]
Akram, Hamzah [5 ]
Ahmad, Mohsin [6 ]
Huselton, Eric [7 ]
机构：
[1] Samaritan Med Ctr, Dept Med, Watertown, NY 13601 USA
[2] Quinnipiac Univ, Frank H Netter MD Sch Med, Bridgeport, CT USA
[3] Univ Michigan, Ann Arbor, MI USA
[4] Univ Ottawa, Ottawa Hosp, Leukemia Fellowship Program, Dept Med,Div Hematol, Ottawa, ON, Canada
[5] Hamilton Hlth Sci, Hamilton, ON, Canada
[6] CHRISTUS Southeast Texas St Elizabeth Hosp, Beaumont, TX USA
[7] Univ Rochester, Dept Hematol Oncol, Rochester, NY USA
来源：
LEUKEMIA RESEARCH REPORTS | 2025年 / 23卷
关键词：
Acute myeloid leukemia; Revumenib; KMT2A; Menin inhibition therapy; INHIBITOR; REVUMENIB;
D O I：
10.1016/j.lrr.2024.100495
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Targeted therapy for fusion-driven high-risk acute leukemia
    Pikman, Yana
    Stegmaier, Kimberly
    BLOOD, 2018, 132 (12) : 1241 - 1247
  • [42] Combination of Menin and IDH Mutant Inhibition in Acute Myeloid Leukemia
    Yoon, James J.
    Miao, Hongzhi
    Purohit, Trupta
    Chen, Dong
    Cierpicki, Tomasz
    Grembecka, Jolanta
    BLOOD, 2022, 140 : 5946 - 5946
  • [43] Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
    Boissel, Nicolas
    Renneville, Aline
    Leguay, Thibaut
    Lefebvre, Pascale Cornillet
    Recher, Christian
    Lecerf, Thibaud
    Delabesse, Eric
    Berthon, Celine
    Blanchet, Odile
    Prebet, Thomas
    Pautas, Cecile
    Chevallier, Patrice
    Lepretre, Stephane
    Girault, Stephane
    Bonmati, Caroline
    Guieze, Romain
    Himberlin, Chantal
    Randriamalala, Edouard
    Preudhomme, Claude
    Jourdan, Eric
    Dombret, Herve
    Ifrah, Norbert
    HAEMATOLOGICA, 2015, 100 (06) : 780 - 785
  • [44] Induction therapy in acute myeloid leukemia: intensifying and targeting the approach
    Fernandez, Hugo F.
    Rowe, Jacob M.
    CURRENT OPINION IN HEMATOLOGY, 2010, 17 (02) : 79 - 84
  • [45] Targeting CD33 for acute myeloid leukemia therapy
    Liu, Jingjing
    Tong, Jiayin
    Yang, Haiping
    BMC CANCER, 2022, 22 (01)
  • [46] Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy
    Castelli, Germana
    Pelosi, Elvira
    Testa, Ugo
    ONCOTARGETS AND THERAPY, 2018, 11 : 131 - 155
  • [47] Targeting CLL-1 for acute myeloid leukemia therapy
    Ma, Hongbing
    Padmanabhan, Iyer Swaminathan
    Parmar, Simrit
    Gong, Yuping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [48] Targeting CLL-1 for acute myeloid leukemia therapy
    Hongbing Ma
    Iyer Swaminathan Padmanabhan
    Simrit Parmar
    Yuping Gong
    Journal of Hematology & Oncology, 12
  • [49] Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases
    Cioccio, Joseph
    Claxton, David
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (04) : 337 - 349
  • [50] Targeting CD33 for acute myeloid leukemia therapy
    Jingjing Liu
    Jiayin Tong
    Haiping Yang
    BMC Cancer, 22
12345